Research & Innovation

Solid Tumors Clinical Trials

Clinical Trials

Exact Sciences 2018-01

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Physician & Study Coordinator

Physician

Nicholas Taylor, MD

Nicholas Taylor, MD

Study Coordinator

Jessicca Rosario, BS

484-526-7952

Jessicca.rosario@sluhn.org


Close

Synopsis

Treatment Agent: N/A

Synopsis: You are being asked to take part in a research study being conducted by Exact Sciences for subjects who have been diagnosed, or who have a suspicion of diagnosis based on imaging, with any solid tumor.

The purpose of this research is to collect blood samples to better understand the biomarkers of patients with breast, lung, colorectal, prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian or esophageal cancer.  Biomarkers are biologic features found in the blood and may be related to cancer risk and detection.  

Close

Inclusion Criteria
  1. Subject is male or female > 18 years of age.
  2. Subject has an untreated primary malignancy of breast, lung, colorectal, prostate, bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian or esophageal cancer.
    OR
    Subject has suspicion of a primary malignancy of bladder, kidney/renal pelvis, or ovarian cancer based on imaging.
  3. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Close

Exclusion Criteria
  1. Any previous cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
  2. Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
  3. Any treatment for the primary malignancy or sites of metastases. Subject may not have started neo-adjuvant chemotherapy, neo-adjuvant radiation therapy, immunotherapy or other treatment and/or surgery prior to blood sample collection.
  4. Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
  5. Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
  6. IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.
  7. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Close

Exelixis XL184-021

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Physician & Study Coordinator

Physician

Gary G Lu, M.D.

Gary Lu, MD, PhD

Study Coordinator

Jillian Timer, RN, BSN
484-503-4156
Jillian.Timer@sluhn.org

Close

Synopsis

Treatment Agent: Cabozantinib, Atezolizumab

Synopsis: You are being asked to take part in this clinical research study because you have one of the following types of cancer: urothelial carcinoma (includes cancer of the bladder, urethra, ureter, and renal pelvis), renal cell carcinoma (kidney cancer), castration-resistant prostate cancer (CRPC), non-squamous non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric/gastroesophageal junction cancer (GC/GEJC), colorectal cancer (CRC), head and neck (H&N) cancer, or differentiated thyroid cancer (DTC). You may have already received standard of care treatment(s) for your cancer and you are no longer benefiting from your recent treatment. If you haven’t received standard of care treatment for your cancer, your doctor will inform you about treatment alternatives before you decide to take part in this study. If you join this study, you will receive a combination of cabozantinib (XL184) and atezolizumab. If you have been diagnosed with urothelial carcinoma or NSCLC and treated with immune checkpoint inhibitor therapy before joining the study, you will either receive the combination therapy of cabozantinib with atezolizumab or cabozantinib alone.

Cabozantinib is an oral anticancer agent which is approved in the United States and in other countries including those in the European Union. Cabozantinib tablets are approved to treat patients with advanced renal cell carcinoma. In addition, cabozantinib is currently being studied in clinical trials for the treatment of multiple cancers, including your type of cancer. Cabozantinib is considered an investigational drug because it has not been approved by any regulatory authorities (including US Food and Drug Administration [FDA]) for use in any cancer types other than RCC to be evaluated in this study. To date, cabozantinib has been generally well tolerated in cancer patients at doses at or above the doses used in this study.

Atezolizumab is a drug given by intravenous (IV) infusion, which is approved in the United States and in the European Union for advanced urothelial carcinoma as initial or later treatment. It is also approved for the treatment of patients with advanced NSCLC who progressed after certain prior therapies. In addition, atezolizumab is currently being studied in clinical trials for the treatment of multiple cancers, including your type of cancer. Atezolizumab is considered an investigational drug because it has not been approved by any regulatory authorities (including US Food and Drug Administration [FDA]) for use in any cancer types other than UC and NSCLC to be evaluated in this study. To date, atezolizumab has been generally well tolerated in cancer patients at a dose used in this study.

Close

Inclusion Criteria
  1. Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
    • Dose-Escalation Stage:
      • Subjects with UC (including renal pelvis, ureter, bladder, urethra) after prior platinum-based therapy, or
      • Subjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapy
    • Expansion Stage:
      • Inoperable locally advanced or metastatic solid tumor (UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC, CRC, H&N cancer, and DTC as outlined above)
  2. Measurable disease per RECIST 1.1 as determined by the investigator.
  3. Tumor tissue material available (archival or recent tumor biopsy)
  4. Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  5. Age eighteen years or older on the day of consent.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  7. Adequate organ and marrow function.
  8. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
  9. Female subjects of childbearing potential must not be pregnant at screening.

Close

Exclusion Criteria
  1. Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5, 7,19 and 20. Other restrictions regarding prior therapy may apply.
  2. Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 4 weeks before first dose of study treatment.
  3. Concomitant anticoagulation with oral anticoagulants.
  4. Subject is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
  5. Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
  6. The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of autoimmune disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV), AIDS-related illness, acute or chronic hepatitis B or C infection, positive test for tuberculosis, moderate to severe hepatic impairment (Child-Pugh B or C).
  7. Pregnant or lactating females.
  8. Previously identified allergy or hypersensitivity to components of the study treatment formulations.
  9. Diagnosis of another malignancy within 2 years before first dose of study treatment.

Close

Tesaro 4020-01-001

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)

Physician & Study Coordinator

Physician

Gary G Lu, M.D.

Gary Lu, MD, PhD

Study Coordinator

Jillian Timer, RN, BSN
484-503-4156
Jillian.Timer@sluhn.org

Close

Synopsis

Treatment Agent: TSR-022 and TSR-042

Synopsis: You are being asked to be in this research study because you have a type of cancer that cannot be removed by surgery and it has grown on or after your latest anti-cancer treatment.

Purpose: To look at the ability of TSR-022 when taken alone or in combination with TSR-042 to make the cancer smaller and to see if it is safe and well tolerated in patients with advanced solid tumors; to confirm  how much TSR-022 should be given and how often when taken by itself; and to confirm how much TSR-022 should be given and how often it should be taken when given with TSR-042 as Combination Drug.

Close

Inclusion Criteria
  1. Female patients must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication if of childbearing potential or be of nonchildbearing potential.
  2. Female patients of childbearing potential (see above) and male patients must agree to use 2 adequate methods of contraception with their partner
  3. ECOG performance status of ≤ 1
  4. Adequate hematologic and organ function

Close

Exclusion Criteria
  1. For Part 1a: anti-CTLA-4, anti-PD-1, anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent within 3 weeks (ie, 21 days) prior to initiation of study treatment
  2. For Parts 1b and 1c: anti-CTLA-4 within 3 weeks (ie, 21 days) prior to initiation of study treatment, prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
  3. For Part 2 combination arm (TSR-022 + TSR-042): prior treatment with anti-PD-1, anti- PD-L1, or anti-PD-L2 agent that resulted in permanent discontinuation due to an AE.
  4. Known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.
  5. Other serious, uncontrolled medical disorders including, but not limited to nonmalignant systemic disease or active infection requiring systemic therapy, immunodeficiency, known history of human immunodeficiency virus (HIV) infection or HIV 1/2 antibodies, known active hepatitis B , active autoimmune disease, history of interstitial lung disease, history of ≥ Grade 3 immune-related AE with prior immunotherapy with the exception of non-clinically significant lab abnormalities.
  6. Pregnant or breast feeding, or expecting to conceive children within the projected duration of the study
  7. Not recovered (ie, to ≤ Grade 1 or to baseline) from treatment-related AEs

Close

Debiopharm Debio 1143-106

SMARTPLUS-106: Debio 1143 a SMAC Mimetic in Combination with Nivolumab in Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial

Physician & Study Coordinator

Physician

Neil D Belman, D.O.

Neil D Belman, D.O.

Study Coordinator

Jillian Timer, RN, BSN
484-503-4156
Jillian.Timer@sluhn.org

Close

Synopsis

Treatment Agent: Debio 1143

Synopsis: The purpose of this research study is to test an already-approved drug called nivolumab combined with an investigational study drug called Debio 1143 (referred to as the study medication).

The study will focus on subjects with specific solid tumors for whom tumors were previously treated with anti-PD-1/PD-L1 therapy as a single therapy (or when used with other cancer therapies), but the tumors have worsened despite treatment. The study will also focus on subjects whose tumors have initially responded, but have stopped responding to treatment.

The study drug is an experimental drug. “Experimental” means that the study drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA). 

Close

Inclusion Criteria
  • Have received at least one prior line of standard systemic chemotherapy in the advanced/unresectable cancer setting (standard adjuvant/neoadjuvant treatment is acceptable if relapse occurred within six months of treatment end)
  • Have progressed or relapsed during or after a prior anti-programmed cell death-1 (PD-1)/ programmed cell death-ligand 1 (PD-L1)-based treatment, given either as a single agent or in combination with standard/approved chemotherapy, tyrosine kinase inhibitors (TKIs), radiotherapy (RT) or other monoclonal antibodies (mAbs) that are not known to modulate/inhibit immune checkpoints (CPIs)
  • Measurable disease (Part B only) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or Gynecologic Cancer Intergroup (GCIG) criteria in Cohort #4 (if applicable) and documented PD during or after prior PD-1/PD-L1 based therapy

Close

Exclusion Criteria
  • Thoracic or head and neck radiation >30 gray (Gy) within the 3 months prior to Cycle 1 Day 1 (C1D1)
  • Have received, in total, more than 3 (i.e. Cohorts 1&2) or 4 (i.e. Cohorts 3&4) lines of prior systemic treatments (including adjuvant or neoadjuvant regimens if relapse within six months prior to C1D1)
  • Liver cirrhosis Child-Pugh score B or C

Close